August 3, 2022

Name of Company: Meiji Holdings Co., Ltd.

Name of Representative: Kazuo Kawamura, CEO, President and Representative Director Code Number: 2269, Prime Market, Tokyo Stock Exchange

Notice concerning Additional Approval in Japan for Freeze-dried, Cell Culture-Derived

Smallpox Vaccine LC16 "KMB" for Prevention of Monkeypox

Meiji Holdings Co., Ltd. announces that its subsidiary, KM Biologics has received approval from the Ministry of Health, Labour and Welfare (MHLW) for its Freeze-dried, Cell Culture-Derived Smallpox Vaccine LC16 "KMB" for an additional indication of prevention of monkeypox on August 2, 2022.

This additional approval will not have a material impact on the consolidated financial results for the fiscal year ending March 31, 2023.

#####

Disclaimer: This English translation is prepared for the readers' convenience. When there are any discrepancies between the original Japanese version and English translation version, the original Japanese version always prevails.

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Meiji Holdings Co. Ltd. published this content on 03 August 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 03 August 2022 07:11:05 UTC.